MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13282 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Marilyn A Huestis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: N-Methyl-3,4-methylenedioxyamphetamine, Models, Biological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Midomafetamine (3,4‐methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post‐traumatic stress disorder in adults. MDMA is metabolized by CYP2D6 and is a strong inhibitor of CYP2D6, as well as a weak inhibitor of renal transporters MATE1, OCT1, and OCT2. A pharmacokinetic phase I study was conducted to evaluate the effects of food on MDMA pharmacokinetics. The results of this study, previously published pharmacokinetic data, and in vitro data were combined to develop and verify MDMA population pharmacokinetic and physiologically based pharmacokinetic models. The food effect study demonstrated that a high‐fat/high‐calorie meal did not alter MDMA plasma concentrations, but delayed T max . The population pharmacokinetic model did not identify any clinically meaningful covariates, including age, weight, sex, race, and fed status. The physiologically based pharmacokinetic model simulated pharmacokinetics for the proposed 120 and 180 mg MDMA HCl clinical doses under single‐ and split‐dose (2 h apart) conditions, indicating minor differences in overall exposure, but lower AUC within the first 4 h and delayed T max when administered as a split dose compared to a single dose. The physiologically based pharmacokinetic model also investigated the drug–drug interaction magnitude by varying the fraction metabolized by a representative CYP2D6 substrate (atomoxetine) and evaluated inhibition of renal transporters. The simulations confirm MDMA is a potent CYP2D6 inhibitor, but likely has no meaningful impact on the pharmacokinetics of drugs sensitive to renal transport. This model‐informed drug development approach was employed to inform drug–drug interaction potential and predict pharmacokinetics of clinically relevant dosing regimens of MDMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, USA.
- Independent Consultant, Durham, North Carolina, USA.
- Rebecca Blanchard Consulting, LLC, Allentown, Pennsylvania, USA.
- Lykos Therapeutics, San Jose, California, USA.
- NMS Labs, Horsham, Pennsylvania, USA.
ORCID-Profile: Marilyn A Huestis, Erin Spargo, Nicholas B Miner, Berra Yazar-Klosinski
Zitieren
APA
Huestis, M. A., Smith, W. B., Leonowens, C., Blanchard, R., Viaccoz, A., Spargo, E., Miner, N. B., & Yazar-Klosinski, B. (2025). MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13282
Vancouver
Huestis MA, Smith WB, Leonowens C, Blanchard R, Viaccoz A, Spargo E, et al. MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13282
BibTeX
@article{Huestis2025,
author = {Huestis, Marilyn A and Smith, William B and Leonowens, Cathrine and Blanchard, Rebecca and Viaccoz, Aurélien and Spargo, Erin and Miner, Nicholas B and Yazar-Klosinski, Berra},
title = {MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13282}
}
EUVIMED